Targeting triglycerides: the rise of Apolipoprotein C3 and Angiopoietin-like protein 3 inhibitors
Document Type
Article
Department
Population Health (East Africa)
Abstract
Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has fueled the search for novel pharmacotherapy options, and multiple medication classes are being explored. Apolipoprotein C3 (APOC3) and angiopoietin-like protein 3 (ANGPTL3) are among the most promising targets. Several novel agents utilizing these pathways, including olezarsen, plozasiran, and zodasiran, are currently under development for the management of elevated TG, with olezarsen approved in 2024 for the management of familial chylomicronemia syndrome. This comprehensive review provides updated insights into the development of novel hypertriglyceridemia treatments.
Publication (Name of Journal)
American Journal of Cardiovascular Drugs
DOI
https://doi.org/10.1007/s40256-025-00748-7
Recommended Citation
Mansoor, T.,
Nambi, V.,
Parikh, S.,
Misra, A.,
Ismayl, M.,
Sullivan, C.,
Sperling, L.,
Virani, S. S.,
Rifai, M. A.,
Koshy, S. K.
(2025). Targeting triglycerides: the rise of Apolipoprotein C3 and Angiopoietin-like protein 3 inhibitors. American Journal of Cardiovascular Drugs.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_popul_health/181